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Systemic insecticide treatment of the
canine reservoir of Trypanosoma cruzi
induces high levels of lethality in Triatoma
infestans, a principal vector of Chagas
disease
Ariel Loza1, Adrianna Talaga2, Gladys Herbas1, Ruben Jair Canaviri1, Thalia Cahuasiri1, Laura Luck1, Alvaro Guibarra1,
Raquel Goncalves2, Juan Antonio Pereira1, Sonia A. Gomez3, Albert Picado3, Louisa Alexandra Messenger4*,
Caryn Bern5 and Orin Courtenay2
Abstract
Background: Despite large-scale reductions in Chagas disease prevalence across Central and South America,
Trypanosoma cruzi infection remains a considerable public health problem in the Gran Chaco region where vector-
borne transmission persists. In these communities, peridomestic animals are major blood-meal sources for
triatomines, and household presence of infected dogs increases T. cruzi transmission risk for humans. To address the
pressing need for field-friendly, complementary methods to reduce triatomine infestation and interrupt T. cruzi
transmission, this study evaluated the systemic activity of three commercial, oral, single dose insecticides Fluralaner
(Bravecto®), Afoxolaner (NexGard®) and Spinosad (Comfortis®) in canine feed-through assays against Triatoma
infestans, the principal domestic vector species in the Southern Cone of South America.
Methods: Twelve healthy, outbred dogs were recruited from the Zoonosis Surveillance and Control Program in
Santa Cruz, Bolivia, and randomized to three treatment groups, each containing one control and three treated
dogs. Following oral drug administration, colony-reared second and third stage T. infestans instars were offered to
feed on dogs for 30 min at 2, 7, 21, 34 and 51 days post-treatment.
Results: Eighty-five per cent (768/907) of T. infestans successfully blood-fed during bioassays, with significantly
higher proportions of bugs becoming fully-engorged when exposed to Bravecto® treated dogs (P < 0.001) for
reasons unknown. Exposure to Bravecto® or NexGard® induced 100% triatomine mortality in fully- or semi-engorged
bugs within 5 days of feeding for the entire follow-up period. The lethality effect for Comfortis® was much lower
(50–70%) and declined almost entirely after 51 days. Instead Comfortis® treatment resulted in substantial morbidity;
of these, 30% fully recovered whereas 53% remained morbid after 120 h, the latter subsequently unable to feed
30 days later.
(Continued on next page)
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Conclusions: A single oral dose of Fluralaner or Afoxolaner was safe and well tolerated, producing complete
triatomine mortality on treated dogs over 7.3 weeks. While both drugs were highly efficacious, more bugs exposed
to Fluralaner took complete blood-meals, and experienced rapid knock-down. Coupled with its longer residual
activity, Fluralaner represents an ideal insecticide for development into a complementary, operationally-feasible,
community-level method of reducing triatomine infestation and potentially controlling T. cruzi transmission, in the
Gran Chaco region.
Keywords: Chagas disease, Triatoma infestans, Dog, Bolivia, Bravecto®, NexGard®, Comfortis®, Spinosad, Fluralaner,
Afoxolaner
Background
Chagas disease, caused by the protozoan parasite Trypa-
nosoma cruzi, is responsible for the highest burden of any
parasitic disease in the Americas; 6 million individuals are
currently infected with a further 70 million at risk [1]. Try-
panosoma cruzi infection has a highly variable clinical
course, ranging from complete absence of symptoms to
severe and often fatal cardiovascular and/or gastrointes-
tinal manifestations [2]. Despite a number of successful
disease control programs in other areas of South America,
intense vector-borne transmission persists in the rural
Gran Chaco straddling Bolivia, Argentina and Paraguay.
In the Bolivian Chaco, more than 80% of adult residents
are infected and triatomine infestation of rural houses re-
mains widespread [3]. In these endemic regions, perido-
mestic animals (dogs, chickens and goats, etc.) are major
blood-meal sources for triatomines, and dogs are the most
important T. cruzi reservoir, linked to high transmission
risk to humans [4, 5]. Vector control is essential to pre-
vent new disease cases. However, in the Bolivian Chaco,
indoor residual spraying has failed to achieve adequate
control due to poor housing conditions, suboptimal
spraying efficacy and intensity, and growing insecticide
resistance [3, 6]. Previous studies have explored insecti-
cidal methods to control the reservoir of T. cruzi infec-
tion in canine hosts, with varying degrees of success;
deltamethrin-treated dog collars reduced vector feeding
success, survival, fecundity and molting rate [7, 8],
while topical application of fipronil had more limited
impact on triatomine mortality [9, 10]. Veterinary feed-
through insecticides have shown efficacy against the
vectors of leishmaniasis and malaria [11–13]. Systemic
insecticides are commercially available and thus easily
accessible, relatively inexpensive, easy to administer in
oral formulations, long-lasting, circulate uniformly in
the blood for consistent vector uptake, have good safety
profiles and impart collateral benefits to treated ani-
mals (for example, simultaneous control of ecto- and
endoparasites). However, to date, no work has been
conducted to assess their effect on triatomines. This
study evaluated the systemic activity of three registered
canine insecticides against Triatoma infestans, the
principal domestic vector of Chagas disease in the
Southern Cone of South America.
Methods
Selection of systemic anti-parasitic compounds
Three insecticide products registered for use in dogs in
the USA/Europe and Bolivia were tested (Table 1), se-
lected amongst other registered products based on the
criteria that they (i) showed evidence of anti-ecto-
parasite activity; (ii) were orally administered, and (iii)
had an effective duration of at least 4 weeks, as de-
scribed fully elsewhere [14]. The label claim of all three
drugs is to combat fleas and ticks, with additional pub-
lished studies showing varying activities against phlebo-
tomine sandflies (vectors of Leishmania and some
viruses) [12, 13]. All candidate products were adminis-
tered in the recommended dose from the manufacturer
(Table 1, Fig. 1a).
Dogs recruitment and maintenance
Dogs were obtained from the Zoonosis Surveillance and
Control Program in the city of Santa Cruz de la Sierra,
Bolivia. The Program routinely collected stray dogs, which
were housed in municipal kennels for 3 days, followed by
euthanasia if unclaimed by their owners. With agreement
from the program, 12 unclaimed dogs were recruited. In-
cluded dogs weighed ≥5 kg and were outbred (mongrels).
Dogs were transferred to purpose-built individual kennels
(W × L × H: 0.97 × 1.30 × 1.70 m) at the Facultad de
Ciencias Veterinarias, Universidad Autonóma Gabriel
René Moreno (UAGRM), Santa Cruz. Dogs were acclima-
tized for 1 month prior to the experiment, where they
were provided with regular nutrition and exercise. This
period was sufficient time to minimize any unseen anti-
parasitic treatment (e.g. ivermectin against Dirofilaria
heart worm, or topical insecticides against fleas and ticks)
that dogs may have received before their capture. The dur-
ation of the experiment was 51 days post-treatment. Dogs
were routinely observed, wholesomely fed and watered,
and exercised twice daily by veterinary staff. At the end of
the experiment, all dogs were adopted, most by veterinary
staff and students.
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Triatomine bug colony maintenance
An F1 generation triatomine colony was established in
the Facultad de Ciencias Veterinarias (UAGRM) starting
with eggs laid by intra-domicillary adult T. infestans col-
lected in the endemic rural village of Itanambikua,
Camiri, between December 2015 and March 2016 (Fig.
1b). The colony was established and amplified by blood-
feeding nymphs and adults every 2–3 weeks on a group
of 20 adult chickens, mildly restrained in a loose fitting
three sided box enclosure, allowing free head movement,
Table 1 Properties of candidate systemic anti-parasitic compounds for canine feed-through assays
Commercial name
(Company)
Active compound
(Family)
Dose
(mg/kg)a
Mode of action Safety
(mg/kg)
Activity
perioda
Reference
Comfortis®
(Elanco Animal Health)
Spinosad (Spinosyns) 45–70 Binds nicotinic acetylcholine
receptors
Oral >3600 4 weeks [30, 34, 40–43]
Bravecto®
(Merck Animal Health)
Fluralaner (Isoxazolines) 25 Non-competitive GABA
receptor antagonist
Oral >2000 12 weeks [14, 18, 19, 27, 37, 44]
NexGard®
(Merial)
Afoxolaner (Isoxazolines) 2.5 Non-competitive GABA
receptor antagonist
Oral >1000 5 weeks [24, 45–48]
aRegistered dose for use in dogs against ticks and fleas [49–51]
Fig. 1 a Three candidate commercial insecticides under evaluation (Bravecto®, NexGard® and Comfortis®). b F1 generation triatomine colony
established from intra-domicillary adult T. infestans collected in Itanambikua, Camiri. c Oral administration of drugs to recruited dogs. d Entomological
bioassays, exposing second and third stage T. infestans instars to treated and control dogs for 30 min at 2, 7, 21, 34 and 51 days post-treatment
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in a semi-darkened room, according to approved ethical
protocols.
Canine feed-through assays
Dogs were randomised into 3 treatment groups each
group comprising 3 treated dogs and 1 untreated (con-
trol) dog. Randomisation was performed by tossing a
coin in the presence of an observer. Following manufac-
turers’ recommendations, insecticides were administered
on the same day as a single oral dose, one drug per
treatment group (Fig. 1c). An entomological bioassay
was performed on treated and control dogs starting
2 days after canine treatment, and at 7, 21, 34 and
51 days later. Bioassays were performed on all dogs on
the same day. The 51-day period of follow-up is the
equivalent of 7.3 weeks which exceeds the 4–5 week ac-
tivity period of Nexgard® and Comfortis®, and represents
over half (61%) of the 12 week activity period of
Bravecto® (Table 1).
Colony reared second and third stage nymphs were
used in the bioassays. Dogs were gently restrained by a
trained veterinary student in a standing or lying down
position to suit the dog’s comfort, and a glass jar with a
net lid containing an average of 15.1 (range of 15–17)
bugs starved for 2–3 weeks was placed on the dog’s ab-
domen and allowed to feed for 30 min (Fig. 1d). Half an
hour was judged to be the time it took for a bug to fully
engorge. Immediately after removing the jar, bugs were
classified visually as fully engorged, semi-engorged, or
non-fed. No bug deaths were observed at this time.
Maintained in the same jar, the bugs were subsequently
monitored at 24, 48, 72, 96 and 120 h post-exposure to
record the numbers alive, dead or moribund.
Statistical analysis
For purposes of analysis, only visibly engorged bugs were
confirmed as exposed; non-fed bugs were considered
unexposed. Moribund bugs were defined as those with
movement impairment (i.e. limited activity and legs
twitching or kicking in the air). The cumulative numbers
of dead and moribund bugs per dog bioassay were com-
puted for each of the five time-points post-canine treat-
ment. The effect of the treatments on T. infestans
mortality and morbidity were analysed separately. Data
were analysed using General Linearised Models (GLM)
for the appropriate Poisson, Binomial or Gausssian un-
transformed data structure, as indicated in the text. Un-
less specified, all analytical models included covariates
describing the experimental structure [insecticide prod-
uct, days post-canine treatment, dog status (control or
treated)] and the interaction terms as appropriate. For
example, to test for the effect of triatomine engorgement
status on mortality estimates, the engorgement status ×
time post treatment interaction term was included in
the model. Data were also analysed using specified non-
parametric tests as required. In an analogy to an Intention
to Treat analysis, we also quantified the efficacy of the
drugs by including all triatomines in the bioassay jar of-
fered to feed on treated dogs irrespective of the bugs’ feed-
ing status outcome (i.e. fed or non-fed). All statistical
analyses were conducted in Stata 13 (StataCorp LP,
College Station, TX).
Results
At the start of the experiment, recruited dogs weighed
an average of 16.3 kg (SD: 5.93; range: 5–29 kg), with an
estimated age of 5.9 yrs. (SD: 3, range: 2–12). There
were no significant differences in the weights or ages of
dogs between treatment groups (GLM: Z < 0.92,
P > 0.36), or between control and treated dogs (GLM:
Z < 0.39, P > 0.70). Furthermore, no adverse events
among any dogs were observed during the study.
A total of 907 colony-reared T. infestans were offered to
feed on the 12 recruited dogs in the 5 follow-up bioassays
conducted from 2 to 51 days post-canine treatment. Of
these bugs, 768 (84.7%) successfully blood-fed and were
therefore classified hereafter as exposed, whereas 15.3%
(139/907) did not feed so exposure was not confirmed,
thus classified as non-exposed (Fig. 2, Table 2).
The per bioassay variation in the crude numbers of
bugs exposed, and of different engorgement status
(Table 3), was not dissimilar between treatment groups
when controlling for the experimental design covariates
[mean number of bugs per jar (potentially exposed):
Poisson GLM Z < 1.93, P > 0.05; mean number of bugs
engorged (exposed): Poisson GLM Z < -1.14, P > 0.25)].
The mean proportions of bugs that blood-fed or that
fully engorged were not significantly different between
treated or control dogs within drug treatment groups
(Wilcoxon signed-rank tests: Z < 0.262, P > 0.793). How-
ever, the proportion of blood-fed bugs that fully (cf. par-
tially) engorged on Bravecto® -treated dogs was higher
than observed for NexGard® or Comfortis® (binomial
GLM: Z > -3.52, P < 0.001); NexGard® or Comfortis®
were not significantly different (Z = 1.55, P = 0.121).
The proportion of bugs that blood-fed, or that were fully
engorged, was not statistically associated with the num-
ber of bugs in the jar potentially exposed during the bio-
assay (GLM: test of number exposed: Z < 1.73, P > 0.08;
test of drug*number exposed interaction terms: Z < 1.41,
P > 0.16). This suggests that feeding success was not
density-dependent.
Treatment lethality effect
Bravecto® and NexGard® induced high levels of T. infes-
tans mortality. The proportion of fed bugs (fully- and
semi-engorged combined) that died by 120 h post-
exposure was 100% in all follow-up bioassays following
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canine treatment (Table 4, Fig. 3). The lethality effect in
dogs treated with Comfortis® reached a median of 50–
70% within 7 days post-canine treatment, but declined
linearly thereafter (Fig. 3). Engorgement status did not
influence the high mortality rates in Bravecto® and
NexGard® treated dogs, whereas there was some evi-
dence that for Comfortis®, mortality was higher in fully-
engorged (median 0.64, binomial 95% CI: 0.14–0.98,
n = 15) compared to semi-engorged bugs (median 0.23,
binomial 95% CI: 0.00–0.63, n = 14) (Wilcoxon signed-
rank test of matched proportional mortality per bioassay
sample post canine treatment: Z = 1.74, P = 0.082; crude
totals 0.50 (48/97) vs 0.32 (31/97) (χ2 = 6.17, P = 0.013).
Three measures of background mortality were ob-
tained. The mortality in triatomines that engorged on
control dogs was zero for all drugs with the exception of
1/14 bugs exposed to Comfortis® on day 51 post-canine
treatment (Table 4). Similarly, mortality amongst non-
exposed (unfed) bugs offered to control dogs was zero
with the exception of 1/2 bugs offered to the Bravecto®
control dog 21-days post-canine treatment. The third
measure was for unexposed bugs in the treated dog
groups, amounting to 11.4% (12/105) across treatments,
with no significant differences detected between drug
treatments (Bravecto® 3/23, Comfortis® 4/36, NexGard®
5/46; χ2 < 0.07, P > 0.79 for each paired test). By com-
parison, mortality in the non-exposed bugs on all con-
trol dogs was 2.9% (1/34), which was not statistically
different (Fisher’s exact test, P = 0.30) (Table 4). How-
ever, crude mortality in non-exposed bugs on treated
dogs was higher than in exposed bugs on control dogs
0.52% (1/191) (Fisher’s exact text, P < 0.001) suggesting
that a proportion of non-exposed bugs on treated dogs
were misclassified and were actually partially fed.
a
b
Fig. 2 Overall feeding success of 907 colony-reared T. infestans
immediately following bioassays (n = 5 bioassays per dog) on
treated (a) and control (b) dogs
Table 2 Summary total numbers of colony-reared T. infestans exposed to dogs, and their feeding success, recorded immediately
after bioassays (n = 5 bioassays per dog)
Status of triatomines after bioassays
Treatment group Potentially exposeda Blood-fedb Fully engorged Semi-engorged Non-fedc
Treated (3 dogs each)
Bravecto® 225 202 153 49 23
Comfortis® 230 194 97 97 36
NexGard® 227 181 87 94 46
Total 682 577 337 240 105
Control (1 dog each)
Bravecto® 75 65 33 32 10
Comfortis® 75 65 36 29 10
NexGard® 75 61 24 37 14
Total 225 191 93 98 34
Overall total 907 768 430 338 139
aNumbers of bugs in the jar placed on the dog’s abdomen and given a choice to feed
bClassified as exposed
cClassified as unexposed
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Treatment morbidity effect
The three drug treatments induced morbidity, defined as
movement impairment post-exposure, in a varying pro-
portion of engorged bugs, and with different progression
outcomes. Morbidity induced by Comfortis® treatment
was observed in a cumulative 47/194 (24%) exposed
bugs in all five follow-up bioassays and on all 3 treated
dogs (Table 5). Bravecto® induced morbidity in only 3%
(6/202) of exposed bugs, and NexGard® in 13% (24/181)
of exposed bugs. The proportions of bugs that showed
Table 3 Variation in the median (binomial 95% CIs) number of bugs, and their proportional engorgement status, recorded
immediately after each dog bioassay (n = 5 bioassays per dog)
Treatment group Bravecto® NexGard® Comfortis®
Treated (3 dogs each)
Total fed (exposed) 13 (13–15) 12 (9.36–14) 13 (12–14.82)
Total in jar (potentially exposed) 15 (15–15) 15 (15–15) 15 (15–15.82)
Proportion feda 0.87 (0.87–1.00) 0.80 (0.62–0.93) 0.87 (0.8–0.94)
Proportion fully engorgeda 0.67 (0.55–0.87) 0.33 (0.21–0.58) 0.40 (0.28–0.52)
Proportion of blood-fed that fully engorged 0.77 (0.67–0.87) 0.39 (0.24–0.73) 0.47 (0.34–0.65)
Control (1 dog each)
Total fed (exposed) 14 (9–15) 15 (4–15) 14 (9–14)
Total in jar 15 (15–15) 15 (15–15) 15 (15–15)
Proportion feda 0.93 (0.60–1.00) 1.00 (0.27–1.00) 0.93 (0.60–0.93)
Proportion fully engorgeda 0.40 (0–0.80) 0.33 (0–0.60) 0.33 (0.07–0.93)
Proportion of blood-fed that fully engorged 0.44 (0–0.86) 0.50 (0–0.60) 0.56 (0.07–1.00)
aProportion of all bugs offered to dogs in the bioassay (i.e. potentially exposed)
Table 4 Summary of mortality amongst exposed and non-exposed T. infestans post-canine treatment bioassaysa
Days post-canine
treatment
Triatomines applied to treated dogs Triatomines applied to control dogs
Proportion (dead/exposed) Dead/Non-exposed Dead/Exposed Dead/Non-exposed
Bravecto®
2 1 (42/42) 0/3 0/9 0/6
7 1 (41/41) 1/4 0/14 0/1
21 1 (43/43) 0/2 0/13 1/2
34 1 (36/36) 1/9 0/14 0/1
51 1 (40/40) 1/5 0/15 0/0
Total 1 (202/202) 0.13 (3/23) 0.0 (0/65) 0.10 (1/10)
Comfortis®
2 0.55 (16/29) 0/17 0/14 0/1
7 0.63 (27/43) 1/4 0/9 0/6
21 0.48 (19/40) 0/5 0/14 0/1
34 0.36 (16/44) 0/2 0/14 0/1
51 0.03 (1/38) 3/8 1/14 0/1
Total 0.41 (79/194) 0.11 (4/36) 0.02 (1/65) 0.0 (0/10)
NexGard®
2 0.97 (29/30) 1/17 0/4 0/11
7 1 (32/32) 0/13 0/12 0/3
21 0.95 (38/40) 0/5 0/15 0/0
34 1 (39/39) 4/6 0/15 0/0
51 1 (40/40) 0/5 0/15 0/0
Total 0.98 (178/181) 0.11 (5/46) 0.0 (0/61) 0.0 (0/14)
Total (3 treatments) 0.11 (12/105) 0.01 (1/191) 0.03 (1/34)
aCumulative numbers dead by 120 h post-triatomine exposure/potential exposure
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signs of morbidity were significantly higher following ex-
posure to Comfortis® than to the other treatments
(χ2 > 10.7, P < 0.0012 in paired comparisons; Kruskal-
Wallis equality-of-populations rank test χ2 = 13.2,
P = 0.0014), but not different between NexGard® and
Bravecto® treatments (Kruskal-Wallis χ2 = 1.0, P = 0.31).
Considering Comfortis® alone, the proportion of mori-
bund exposed bugs significantly declined with increasing
time from canine treatment (Wilcoxon rank-sum test for
trend: Z = -2.40, P = 0.016). Similar patterns were seen
in fully- and semi-engorged bugs (comparison of days
post-treatment*engorgement status interaction, GLM bi-
nomial, Z = -0.73, P = 0.46) (Table 5, Fig. 4).
Both Bravecto® and NexGard® induced morbidity in
the 51-days post-treatment bioassay only; Bravecto® af-
fected 3 semi- and 3 fully-engorged bugs in bioassays on
2 dogs, whereas NexGard® affected 2 partially and 22
fully-fed bugs in bioassays on the 3 dogs. However, these
treatments were not considered sub-lethal doses as
100% (Bravecto®: 6/6; NexGard®: 24/24) of these bugs
died within 48 h after feeding (Table 6).
In contrast, morbidity induced by Comfortis® treat-
ment was observed in all 5 follow-up bioassays on the 3
treated dogs (Table 6). Of the 47 morbid exposed bugs,
only 17% (8/47) were dead by the end of the 120 h post-
exposure; 4 died within 48 h of feeding, and 4 delayed to
72 and 120 h post-feeding, respectively. Morbidity per-
sisted in 53% (25/47) of these bugs by the end of the
120 h observation period, whereas 30% (14/47) appeared
to have recovered to full activity within this time frame
(Table 6).
No morbidity was observed among the non-exposed
bugs on Comfortis® treated dogs, bugs on Comfortis®
control dogs, or bugs exposed or non-exposed on
Bravecto® control dogs (Table 5). Only 1 non-exposed
bug on the NexGard® control dog showed signs of
morbidity.
Impact of morbidity on triatomine feeding success
To test if moribund T. infestans could successfully feed,
and thus be potentially infectious, 8 partially-fed mori-
bund bugs and 7 active control bugs that had been
Fig. 3 Proportional mortality of bugs exposed to each drug in post-canine treatment bioassays. Mortality in control dogs were zero except 1 death in
the Comfortis group® (data not shown; see Table 4). Data are medians and binomial estimates of 95% CIs (error bars). Bravecto® and NexGard®
displayed 100% mortality in treated dogs but is offset for clarity
Table 5 Summary of proportion morbid T. infestans in the Comfortis® treatment group (n = 5 bioassays per dog)
Days post-canine
treatment
Treated dogs Control dogs
Exposeda Fully engorged Partially engorged Non-exposedb Non-exposed
and exposed
2 0.38 (11/29) 0.36 (4/11) 0.39 (7/18) 0 (0/17) 0 (0/15)
7 0.37 (16/43) 0.32 (9/28) 0.47 (7/15) 0 (0/4) 0 (0/15)
21 0.28 (11/40) 0.29 (5/17) 0.26 (6/23) 0 (0/5) 0 (0/15)
34 0.14 (6/44) 0.07 (1/15) 0.17 (5/29) 0 (0/2) 0 (0/15)
51 0.08 (3/38) 0.12 (3/26) 0.0 (0/12) 0 (0/8) 0 (0/15)
Total 0.24 (47/194) 0.23 (22/97) 0.26 (25/97) 0.0 (0/36) 0.0 (0/75)
aBlood-fed triatomines were classified as exposed
bNon-engorged triatomines classified as non-exposed
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exposed to 3 different dogs 21 days post-canine treat-
ment with Comfortis®, were subsequently exposed to a
new, non-treated dog 30 days post-bug exposure (at the
51 day follow-up). None of the moribund bugs
attempted to feed (0/2, 0/1 and 0/5 per dog), whereas 6/
7 (86%; 1/1, 2/3 and 3/3) of the control bugs attempted
and successfully fed.
Intention to treat analysis
In an “Intention to Treat” analysis, the efficacy of the
drugs to kill T. infestans was 91% (95% CI: 79.1–100%),
81% (95% CI: 69.4–93.2%) and 36% (95% CI: 28.7–
44.7%) for Bravecto®, NexGard®, and Comfortis®, respect-
ively. The equivalent analysis for induced morbidity were
3% (95% CI: 1.0–5.8%), 11% (95% CI: 7.1–16.3%), and
20% (95% CI: 15.0–27.2%) for the three drugs. Out of 75
bugs offered to each control dog, only 1 died in each of
the Bravecto® and Comfortis® treatment groups, and no
bugs showed signs of morbidity in any treatment group.
Analysis of the odds ratios associated with drug in-
duced mortality showed that in comparison to Bravecto®
(referent), the odds of mortality from NexGard® were
0.70 (95% CI: 0.502–0.982) and from Comfortis® 0.17
(95% CI: 0.122–0.246). The odds of inducing morbidity
compared to Bravecto® were 8.9 (95% CI: 3.76–21.22)
and 4.4 (95% CI: 1.79–10.94) for NexGard® and Comfor-
tis®, respectively.
Discussion
Of the three candidate drugs under evaluation, Bravecto®
and NexGard® demonstrated the most promising results.
Both compounds induced and sustained high levels of
triatomine mortality, killing all bugs within 120 h of
feeding for 51 days post-canine treatment. By contrast,
the initial lethality effect of Comfortis® was much lower
and had declined almost entirely by the end of the ex-
periment. While mortality was the primary outcome of
Bravecto® and NexGard® exposure, Comfortis® treatment
resulted in substantial morbidity. One third of these ini-
tially moribund bugs fully recovered within five days
post-exposure, whereas over half remained in a morbid
state for at least five days post-exposure, but were subse-
quently unable to feed even 30 days later. In addition to
its efficacy and residual activity, Bravecto® also displayed
Fig. 4 Morbidity of fully- and semi-engorged bugs exposed to Comfortis® post canine treatment. The 95% CIs represent the variation between
individual dogs
Table 6 Fate of initially morbid bugs post-exposure
Treatment Initial proportion
(morbid/exposed)
Fate of morbid bugs Proportion
(number/initially morbid)a
Remained morbid Dead Recovered
Bravecto® 0.03 (6/202) 0 (0/6) 1 (6/6) 0 (0/6)
NexGard® 0.13 (24/181) 0 (0/24) 1 (24/24) 0 (0 /24)
Comfortis® 0.24 (47/194) 0.53 (25/47) 0.17 (8/47) 0.30 (14/47)
aFate recorded as outcome after 120 h follow-up observation period post-exposure
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two other advantageous characteristics; significantly
more fed bugs took complete blood meals, potentially
maximizing their likelihood of receiving a lethal dose
especially once canine plasma levels begin to fall, and
exposure produced more immediate knockdown, com-
pared to the other two drugs. Why higher proportions of
bugs fully-engorged on Bravecto® treated dogs than the
other two drugs, which was consistent from time of
treatment, is not known; the data do not suggest an
anti-feeding effect of the other systemic insecticides.
Accounting for this difference in an Intention to Treat
analysis, Bravecto® proved to induce higher mortality
and lower morbidity.
The generally analogous results demonstrated by
Bravecto® and NexGard® can be explained by their simi-
lar mechanistic pathways. Fluralaner and Afoxolaner are
members of the isoxazoline family and potent antago-
nists of γ-aminobutyric acid (GABA)- and L-glutamate-
gated chloride channels, resulting in irreversible hyper-
excitation, with significant selectivity for arthropod vs
mammalian neurons [15]. Both compounds have good
mammalian safety profiles and are highly efficacious
against medically-important vectors and other arthro-
pods [14, 16, 17]. A single dose of Bravecto® achieved
>99% mortality of canine fleas, Rhipicephalus, Ixodes
and Dermacentor ticks and Demodex mites, over
12 weeks, with measurable plasma concentrations de-
tected up to 112 days post canine-treatment; mean half-
life was estimated at 15 days [18–20]. Fluralaner has also
outperformed a number of other topical insecticides and
systemic insecticides, including fipronil, sarolaner, imida-
cloprid and permethrin against Rhipicephalus sangui-
neus and dieldrin to control Ctenocephalides felis, Aedes
aegypti and Lucilia cuprina [15, 21]. Similarly, a single
dose of NexGard®, reduced populations of C. felis by
100% within 24 h and blocked egg production by >99%
over 36 days [22, 23]; additional re-treatment at days
28–30, achieved total flea control by 60 days [24]. Other
studies of single doses of NexGard® report complete
elimination of pre-existing Dermacentor reticulatus, D.
variabilis and Ixodes ricinus infestations and sustained
efficacy of >96% one month later [25, 26] and significant
reductions in R. sanguineus and Haemaphysalis longicor-
nis by >96% after 35 days [27] and 92% after 30 days
[28], respectively; maximum plasma levels are observed at
2–6 h and mean half-life is 15.5 days [17]. A direct com-
parison of immediate efficacy of Bravecto® and NexGard®
against R. sanguineus demonstrated that onset of activity
was 4 h and 8 h, respectively, and 100% mortality was
achieved within 12 h and 48 h, respectively [21].
By comparison, Comfortis® is a mixture of two spino-
syns (spinosyn A and D), which preferentially binds to
nicotinic acetylcholine receptors (nAChRs), with second-
ary activity against GABA-receptors [29]. This drug can
also be a potent pulicide, reducing C. felis burdens by
>99 and 97–98% three and four weeks post-treatment in
laboratory infestations, respectively, and by >99% after a
90 day multi-country community trial [30]. Other inves-
tigators have presented more variable residual activities
against fleas over 28 days [31, 32]. In contrast to our re-
sults, previous studies have reported complete knock-
down of established flea populations [33] and 100%
mortality within 4 h [31], coinciding with peak canine
spinosad plasma levels, between 2 to 4 h post-treatment
[30]. Spinosyns have also demonstrated high levels of ef-
ficacy against Phlebotomus papatasi feeding on treated
hamsters (5000 mg/kg), producing 100% sand fly mortal-
ity for one week; mortality declined to 14.2% by day 14
[34]. In addition to triatomines likely requiring higher
concentrations of the active ingredient than fleas and
smaller arthropods, other possible explanations for our
observations include that a lower proportion of triato-
mines became fully-engorged following Comfortis® ex-
posure, compared to those feeding on Bravecto®-treated
dogs, and/or systemic concentrations had already begun
to fall by the first time-point; mean elimination half-life
for spinosad ranges from 128 to 163 h [35]. Because
Comfortis® elicited the lowest levels of triatomine mor-
tality, had the shortest residual activity, and given re-
ports of the potential presence of naturally-resistant
triatomine populations in neighbouring Argentina [36],
this compound does not currently warrant further con-
sideration for control of T. infestans populations in
Bolivia. Notwithstanding, screening of a wide range of
drugs with different modes of action for potential rota-
tion in a community-setting, remains important to re-
duce the risk of natural and acquired resistance.
When evaluating oral insecticides to develop into a
community-level control strategy, compounds need to
demonstrate high and sustained anti-triatomine efficacy,
long residual activity to reduce re-treatment times, be ad-
ministrable to a large number of dogs, safe in case one
dog receives multiple doses, and provide additional bene-
fits, such promoting improved nutritional status and con-
trol of other ecto- and endo-parasites. In this regard,
Bravecto® emerges as the optimal candidate product based
on its high levels of knockdown, mortality and longest
reported residual activity. Furthermore, ingestion of
Bravecto® with food was previously shown to increase total
drug exposure over 91 days and was 2.5 times greater than
in dogs treated while fasting [37].
The aim of the current study was to demonstrate proof
of principle of the systemic lethality of candidate oral insec-
ticides against triatomine bugs and thus there are some lim-
itations which must be considered when interpreting the
results. For logistical reasons, the study was not blinded to
the personnel handling the dogs. The background mortality
in unexposed bugs on treated dogs across treatments was
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significantly higher than in exposed bugs on control dogs,
but not different for non-exposed bugs on control dogs.
The former result raises the possibility that a proportion of
the bugs on treated dogs were misclassified as non-fed
(non-exposed) via visual inspection rather than by micro-
scopic examination to detect small amounts of blood. We
necessarily reduced handling of triatomines in this study to
minimize any experimental mortality due to the fragility of
the smaller instars. However, this does not appear to have
introduced any discernable bias as the three drugs demon-
strated consistent mortality rates amongst exposed bugs.
While we did not expect to observe dramatic differences in
drug efficacy between different development stages, suscep-
tibility to other insecticides is reported to be more variable
[38, 39]. In this study, we elected to evaluate second and
third instars for operational reasons and for logistics of col-
ony production. In a community scenario, all five triato-
mine stages are capable of harbouring T. cruzi but younger,
immature bugs must take additional blood meals to de-
velop, providing more opportunities for T. cruzi transmis-
sion; these instars would also likely be killed by lower
insecticide concentrations and therefore are the ideal life-
cycle stage to target. We also chose to use outbred, local
dogs, which ranged in terms of age, weight and probably
micronutritional status, again to simulate as true to life re-
sults as possible. This study was conducted for 7.3 weeks as
a compromise between the predicted activity periods of all
three candidate drugs. By the final time-point Bravecto®
and NexGard®, which were assumed to remain efficacious
for at least 12 and 5 weeks, respectively, were still killing all
exposed bugs. Future studies with longer follow-up times
are required to determine the residual duration of these
two compounds and their rate of decline, complemented
by assays measuring both canine plasma levels and concen-
trations of active ingredients imbibed by triatomines. Fur-
thermore, this experimental design could be expanded to
establish the minimum effective doses for T. infestans to in-
form the frequency of re-treatment required in a commu-
nity setting and to investigate the impact of sub-lethal
doses on triatomine morbidity, longevity and fecundity.
Conclusion
A single oral dose of Bravecto® or NexGard®, two isoxazo-
line compounds, commercially available and registered for
tick and flea control in dogs and cats, were safe and well
tolerated, producing 100% triatomine mortality within
5 days of feeding on treated dogs over 7.3 weeks. While
both drugs were highly efficacious, more triatomines ex-
posed to Bravecto® were immediately knocked-down and
took complete blood-meals, potentially maximizing their
likelihood of receiving a lethal dose. Coupled with the
likely longer residual activity of Bravecto® compared to
NexGard® (12 vs 5 weeks, respectively), to reduce re-
treatment times and to address issues of longer-term
sustainability, Bravecto® represents an ideal candidate sys-
temic insecticide for development into a complementary,
operationally-feasible, community-level method of redu-
cing triatomine infestation and potentially interrupting T.
cruzi transmission. Notwithstanding the current cost of
Bravecto® being somewhat higher than that of NexGard®, a
strategy to apply an oral veterinary drug to combat a pub-
lic health problem would be suited to both hyperendemic
regions, such as the Gran Chaco, and low endemic regions
e.g. Costa Rica, where dogs remain an important reservoir
for onward transmission.
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